Clinical Trials Browser

INDUSTRY × Neurofibrosarcoma × Gastrointestinal × Clear all

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05732831 2026-04-06

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

225 enrolled

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07244835 2025-12-08

A Study of DEG6498 in Participants With Solid Tumors

Phase 1 Recruiting

100 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Glioblastoma, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Neurofibrosarcoma

NCT05245500 2025-12-05

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Phase 1 Recruiting

336 enrolled

GastrointestinalOther solid neoplasmSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms, Neurofibrosarcoma

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

30 enrolled

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

Clinical Trials

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

A Study of DEG6498 in Participants With Solid Tumors

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA